Cytotoxic T Lymphocyte Immunity Research Articles

Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis

Lymphatic vessels (LVs) are crucial for maintaining abdominal fluid homoeostasis and immunity. In cirrhosis, mesenteric LVs (mLVs) are dilated and dysfunctional. Given the established role of vascular endothelial growth factor-C (VEGF-C) in improving LVs, we hypothesised that VEGF-C treatment could ameliorate the functions of mLVs in cirrhosis. In this study, we developed a nanoformulation comprising LV-specific growth factor, recombinant human VEGF-C (Cys156Ser) protein (E-VEGF-C) and delivered it orally in different models of rat cirrhosis to target mLVs. Cirrhotic rats were given nanoformulation without VEGF-C served as vehicles. Drainage of mLVs was analysed using tracer dye. Portal and systemic physiological assessments and computed tomography were performed to measure portal pressures and ascites. Gene expression and permeability of primary mesenteric lymphatic endothelial cells (LyECs) was studied. Immune cells in mesenteric lymph nodes (MLNs) were quantified by flow cytometry. Endogenous and exogenous gut bacterial translocation to MLNs was examined. In cirrhotic rats, mLVs were dilated and leaky with impaired drainage. Treatment with E-VEGF-C induced proliferation of mLVs, reduced their diameter, and improved functional drainage. Ascites and portal pressures were significantly reduced in E-VEGF-C rats compared with vehicle rats. In MLNs of E-VEGF-C animals, CD8+CD134+ T cells were increased, whereas CD25+ regulatory T cells were decreased. Both endogenous and exogenous bacterial translocation were limited to MLNs in E-VEGF-C rats with reduced levels of endotoxins in ascites and blood in comparison with those in vehicle rats. E-VEGF-C treatment upregulated the expression of vascular endothelial-cadherin in LyECs and functionally improved the permeability of these cells. E-VEGF-C treatment ameliorates mesenteric lymph drainage and portal pressure and strengthens cytotoxic T-cell immunity in MLNs in experimental cirrhosis. It may thus serve as a promising therapy to manage ascites and reduce pathogenic gut bacterial translocation in cirrhosis. A human recombinant pro-lymphangiogenic growth factor, VEGF-C, was encapsulated in nanolipocarriers (E-VEGF-C) and orally delivered in different models of rat liver cirrhosis to facilitate its gut lymphatic vessel uptake. E-VEGF-C administration significantly increased mesenteric lymphatic vesselproliferation and improved lymph drainage, attenuating abdominal ascites and portal pressures in the animal models. E-VEGF-C treatment limited bacterial translocation to MLNs only with reduced gut bacterial load and ascitic endotoxins. E-VEGF-C therapy thus holds the potential to manage ascites and portal pressure and reduce gut bacterial translocation in patients with cirrhosis.

A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).

TPS7588 Background: First-line therapy for high-burden FL and MZL includes immunochemotherapy (most commonly rituximab with bendamustine), which is associated with toxicities, is not curative, and leads to a prolonged T-cell depletion. The alternative of rituximab with full-dose lenalidomide did not improve efficacy or toxicity [Morschhauser et al., NEJM 2018]. However, lower-dose, short-course lenalidomide (15mg) may enhance cytotoxic T-cell immunity and efficacy of rituximab [Zucca et al, Blood 2019]. Mosunetuzumab is a CD20xCD3-binding, T-cell-engaging bispecific antibody approved for relapsed/refractory FL after 2 lines of therapy. It results in a complete response (CR) rate of 60% in that setting [Budde et al., Lancet Oncol, 2022], despite prior exposure to immunosuppressive therapies. This trial proposes a novel therapeutic approach to first-line treatment of FL/MZL, exploring 3 hypotheses: 1) that mosunetuzumab will lead to a high rate of CR, and possibly eradication, of FL/MZL when applied before exposure to immunosuppressive modalities; 2) that low-dose lenalidomide can augment the cytotoxic T-cell response when CR is not achieved with mosunetuzumab alone, and 3) that baseline host immune environment measured in treatment-naïve state can predict CR to bispecific antibody therapy. Methods: The Brown University Oncology Research Group BrUOG-401/ML43251 ( NCT04792502 ) is an investigator-initiated, multi-center, single-arm, phase 2 clinical trial for patients (pts) with FL and MZL in need of first-line systemic therapy. Pts with FL must meet the Groupe d’Etude des Lymphomes Folliculaires (GELF) criteria of high-burden disease, whereas pts with MZL must require therapy in the investigators’ opinion. As of January 2023, 7 of the planned 52 pts have been enrolled. The trial uses a response-adapted design: pts start with 4 courses of subcutaneous mosunetuzumab monotherapy, using step-up dosing during Cycle 1 (5mg → 45mg → 45mg) to mitigate the risk of cytokine release syndrome (CRS). Pts attaining CR (by Lugano criteria) after Cycle 4 continue for a total of 8 cycles of mosunetuzumab monotherapy. Pts attaining partial response or stable disease receive 4 additional cycles of mosunetuzumab with low-dose lenalidomide augmentation (10mg daily), with further 4 cycles of mosunetuzumab/lenalidomide if CR after C8 is still not attained. The primary endpoints include the ORR and CR rate at final assessment, and rates of toxicities, particularly CRS, tumor flare, and immune-mediated events. PFS and rate of progression of disease at 24 months (POD24) are among secondary endpoints. The study uses Simon’s two-stage design, with the null hypothesis that the CR rate is 53% (based on prior RELEVANCE trial). Correlative studies aim at determining predictive biomarkers of response, including immune signatures and dynamics of circulating tumor DNA during study therapy. Clinical trial information: NCT04792502 .

Dynamics of a Diffusive HBV Infection Model with Capsids, Two Delays, and Cell-to-Cell Transmissions

This article aims to study a hepatitis B virus (HBV) infection model incorporating two nonlinear incidences and spatial diffusion in capsids, virus, and cytotoxic T lymphocyte (CTL) immune response. Three equilibria which are infection-free, immune-free, and infection with CTL immunity are calculated under rational assumptions. Furthermore, two reproduction numbers are verified to assert the global stability of the HBV model. In the end, the theoretical results on HBV dynamics are further illustrated by performing numerical simulations.

Case Review of Alternative Treatment in Patient With Immunotherapy Induced Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Objective To emphasize recognition of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) due to Immune checkpoint inhibitor (ICI) therapy Atezolizumab and efficacy of steroids in treatment. Background Atezolizumab is an anti-programmed death-ligand 1 (PD-L1) immune-modulating drug that induces tumor-specific cytotoxic T-cell immunity against the PD-L1 overexpression of many aggressive lung cancers. IVIG was initially thought to have the same benefit in immunotherapy mediated CIDP however recent cases suggest better benefit with plasmapheresis and steroids. Design/Methods We report a case of CIDP in a 61-year-old female with high grade neuroendocrine carcinoma of the lung with extensive metastasis. After confirmation of diagnosis, patient began treatment with whole brain radiation therapy and 6 cycles of carboplatin/etoposide followed by atezolizumab maintenance every 21 days for 38 months. Initial treatment reaction included self-resolving loss of balance. Last dose of atezolizumab was given 9 days prior to brain biopsy of left frontal mass. Following biopsy, symptoms of generalized weakness and bilateral lower extremity weakness presented. When symptoms progressed, patient was admitted to hospital, 2-3 weeks after last dose of atezolizumab. Results The patient responded to treatment with steroids and cessation of atezolizumab, carboplatin, and etoposide. She recovered to her neurological baseline after a course of IV dexamethasone. Conclusions Among ICI therapy, atezolizumab has been less frequently reported with neurologic adverse events than other medications of its class. Increased recognition of the association between ICI and CIDP may improve early detection and improve potentially fatal outcomes. This case and an assessment of the literature indicate ICI induced CIDP may not respond to IVIG and plasmapheresis treatment with consistency. Although IVIG and plasmapheresis maintained efficiency in some reports, adverse outcomes of IVIG treatment may indicate alternative first-line treatment. This case reports successful recovery with the sole use of immunosuppressive therapy which should be considered to optimize future outcomes of ICI associated CIDP.

Global stability of a general HTLV-I infection model with Cytotoxic T-Lymphocyte immune response and mitotic transmission

Mathematical models have been considered as a robust tool to support biological and medical studies of human viral infections. The global stability of viral infection models remains an important and largely open research problem. Such results are necessary to evaluate treatment strategies for infections and to establish thresholds for treatment rates. Human T-lymphotropic virus class I (HTLV-I) is a retrovirus which infects the CD4+T cells and causes chronic and deadly diseases. In this article, we developed a general nonlinear system of ODEs which describes the within-host dynamics of HTLV-I under the effect Cytotoxic T-Lymphocytes (CTLs) immunity. The mitotic division of actively infected cells are modeled. We consider general nonlinear functions for the generation, proliferation and clearancerates for all types of cells. The incidence rate of infection is also modeled by a general nonlinear function. These general functions are assumed to satisfy a set of suitable conditions and include several forms presented in the literature. We determine a bounded domain for the system’s solutions. We prove the existence of the system’s equilibrium points and determine two threshold numbers, the basic reproductive number R0 and the CTL immunity stimulation number R1. We establish the global stability of all equilibrium points by constructing Lyapunov function and applying Lyapunov-LaSalle asymptotic stability theorem. Under certain conditions it is shown that ifR0≤1, then the infection-free equilibrium point is globally asymptotically stable (GAS) and the HTLV-I infection is cleared. If R1≤1<R0, then the infected equilibrium point without CTL immunity is GAS and the HTLV-I infection becomes chronic with no sustained CTL immune response. If R1>1, then the infected equilibrium point with CTL immunity is GAS and the infection becomes chronic with persistent CTL immune response. We present numerical simulations for the system by choosing special shapes of the general functions. The effect of Crowley-Martin functional response and mitotic division of actively infected cells on the HTLV-I progression are studied. Our results cover and improve several ones presented in the literature.

LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer.

BackgroundThe expression of long non‐coding RNA (lncRNA) prostate cancer‐associated ncRNA transcripts 1 (PCAT1) is increased in non‐small cell lung cancer (NSCLC). It stimulates tumour growth and metastasis, but its role in the radioimmune responses remain unknown. We aimed to explore the impacts of PCAT1 on tumorigenesis and radioimmune responses and the underlying molecular mechanisms in NSCLC.MethodsComprehensive bioinformatics analysis was performed to identify immunosuppressive lncRNAs involved with tumour invasion in NSCLC. The expression levels of PCAT1 were analysed by in situ hybridisation in 55 paired NSCLC tissues and adjacent normal tissues. Both loss‐ and gain‐of‐function assays were performed to examine the effects of PCAT1 and SOX2 on NSCLC cell behaviours in vivo and in vitro. Bioinformatic analyses, chromatin isolation by RNA purification (ChIRP) and dual‐luciferase reporter assays were applied to validate the regulatory effects of PCAT1 on SOX2 expression. Chromatin immunoprecipitation, luciferase and rescue assays were utilised to identify the relationship between SOX2 and the cGAS/stimulator of interferon genes (STING) signalling.ResultsPCAT1 was immunosuppressive and related with NSCLC invasion. Increased PCAT1 was negatively correlated with immune cell infiltration in NSCLC. PCAT1 knockdown restrained proliferation, increased apoptosis, and repressed cell metastasis in vivo and in vitro. PCAT1 activated SOX2 that accelerated tumorigenesis and immunosuppression. SOX2 promoted tumour growth through inhibiting cytotoxic T‐cell immunity. Moreover, SOX2 restrained cGAS transcription and hampered downstream type I interferon (IFN)‐induced immune responses. Inhibition of PCAT1/SOX2 in collaboration with radiation further inhibited tumour growth, and initiated the cGAS/STING signalling pathway, which enhanced the immune responses of radiotherapy in NSCLC.ConclusionsPCAT1/SOX2 axis promoted tumorigenesis and immunosuppression through inhibition of cGAS/STING signalling‐mediated T‐cell activation. Inhibition of PCAT1 and SOX2 synergised with radiotherapy to activate the immune response and could serve as potential therapeutic targets.

Evolutionary conservation and positive selection of influenza A nucleoprotein CTL epitopes for universal vaccination.

Influenza (flu) infection is a leading cause of respiratory diseases and death worldwide. Although seasonal flu vaccines are effective at reducing morbidity and mortality, such effects rely on the odds of successful prediction of the upcoming viral strains. Additional threats from emerging flu viruses that we cannot predict and avian flu viruses that can be directly transmitted to humans urge the strategic development of universal vaccination that can protect against flu viruses of different subtypes and across species. Annual flu vaccines elicit mainly humoral responses. Under circumstances when antibodies induced by vaccination fail to recognize and neutralize the emerging virus adequately, virus‐specific cytotoxic T lymphocytes (CTLs) are the major contributors to the control of viral replication and elimination of infected cells. Our studies exploited the evolutionary conservation of influenza A nucleoprotein (NP) and the fact that NP‐specific CTL responses pose a constant selecting pressure on functional CTL epitopes to screen for NP epitopes that are highly conserved among heterosubtypes but are subjected to positive selection historically. We identified a region on NP that is evolutionarily conserved and historically positively selected (NP137–182) and validated that it contains an epitope that is functional in eliciting NP‐specific CTL responses and immunity that can partially protect immunized mice against lethal dose infection of a heterosubtypic influenza A virus. Our proof‐of‐concept study supports the hypothesis that evolutionary conservation and positive selection of influenza NP can be exploited to identify functional CTL epitope to elicit cross‐protection against different heterosubtypes, therefore, to help develop strategies to modify flu vaccine formula for a broader and more durable protective immunity.

Stability analysis of general delayed HTLV-I dynamics model with mitosis and CTL immunity.

This paper formulates and analyzes a general delayed mathematical model which describe the within-host dynamics of Human T-cell lymphotropic virus class I (HTLV-I) under the effect Cytotoxic T Lymphocyte (CTL) immunity. The models consist of four components: uninfected CD$ 4^{+} $T cells, latently infected cells, actively infected cells and CTLs. The mitotic division of actively infected cells are modeled. We consider general nonlinear functions for the generation, proliferation and clearance rates for all types of cells. The incidence rate of infection is also modeled by a general nonlinear function. These general functions are assumed to be satisfy some suitable conditions. To account for series of events in the infection process and activation of latently infected cells, we introduce two intracellular distributed-time delays into the models: (ⅰ) delay in the formation of latently infected cells, (ⅱ) delay in the activation of latently infected cells. We determine a bounded domain for the system's solutions. We calculate two threshold numbers, the basic reproductive number $ R_{0} $ and the CTL immunity stimulation number $ R_{1} $. We determine the conditions for the existence and global stability of the equilibrium points. We study the global stability of all equilibrium points using Lyapunov method. We prove the following: (a) if $ R_{0}\leq 1 $, then the infection-free equilibrium point is globally asymptotically stable (GAS), (b) if $ R_{1}\leq 1 < R_{0} $, then the infected equilibrium point without CTL immunity is GAS, (c) if $ R_{1} > 1 $, then the infected equilibrium point with CTL immunity is GAS. We present numerical simulations for the system by choosing special shapes of the general functions. The effects of proliferation of CTLs and time delay on the HTLV-I progression is investigated. We noted that the CTL immunity does not play the role in clearing the HTLV-I from the body, but it has an important role in controlling and suppressing the viral infection. On the other hand, we observed that, increasing the time delay intervals can have similar influences as drug therapies in removing viruses from the body. This gives some impression to develop two types of treatments, the first type aims to extend the intracellular delay periods, while the second type aims to activate and stimulate the CTL immune response.

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

AbstractAberrant B-cell receptor/NF-κB signaling is a hallmark feature of B-cell non-Hodgkin lymphomas, especially in diffuse large B-cell lymphoma (DLBCL). Recurrent mutations in this cascade, for example, in CD79B, CARD11, or NFKBIZ, and also in the Toll-like receptor pathway transducer MyD88, all deregulate NF-κB, but their differential impact on lymphoma development and biology remains to be determined. Here, we functionally investigate primary mouse lymphomas that formed in recipient mice of Eµ-myc transgenic hematopoietic stem cells stably transduced with naturally occurring NF-κB mutants. Although most mutants supported Myc-driven lymphoma formation through repressed apoptosis, CARD11- or MyD88-mutant lymphoma cells selectively presented with a macrophage-activating secretion profile, which, in turn, strongly enforced transforming growth factor β (TGF-β)-mediated senescence in the lymphoma cell compartment. However, MyD88- or CARD11-mutant Eµ-myc lymphomas exhibited high-level expression of the immune-checkpoint mediator programmed cell death ligand 1 (PD-L1), thus preventing their efficient clearance by adaptive host immunity. Conversely, these mutant-specific dependencies were therapeutically exploitable by anti–programmed cell death 1 checkpoint blockade, leading to direct T-cell–mediated lysis of predominantly but not exclusively senescent lymphoma cells. Importantly, mouse-based mutant MyD88- and CARD11-derived signatures marked DLBCL subgroups exhibiting mirroring phenotypes with respect to the triad of senescence induction, macrophage attraction, and evasion of cytotoxic T-cell immunity. Complementing genomic subclassification approaches, our functional, cross-species investigation unveils pathogenic principles and therapeutic vulnerabilities applicable to and testable in human DLBCL subsets that may inform future personalized treatment strategies.

Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2

SummaryWe describe a physics-based learning model for predicting the immunogenicity of cytotoxic T lymphocyte (CTL) epitopes derived from diverse pathogens including SARS-CoV-2. The model was trained and optimized on the relative immunodominance of CTL epitopes in human immunodeficiency virus infection. Its accuracy was tested against experimental data from patients with COVID-19. Our model predicts that only some SARS-CoV-2 epitopes predicted to bind to HLA molecules are immunogenic. The immunogenic CTL epitopes across all SARS-CoV-2 proteins are predicted to provide broad population coverage, but those from the SARS-CoV-2 spike protein alone are unlikely to do so. Our model also predicts that several immunogenic SARS-CoV-2 CTL epitopes are identical to seasonal coronaviruses circulating in the population and such cross-reactive CD8+ T cells can indeed be detected in prepandemic blood donors, suggesting that some level of CTL immunity against COVID-19 may be present in some individuals before SARS-CoV-2 infection.

Crystal structure of the giant panda MHC class I complex: First insights into the viral peptide presentation profile in the bear family.

The viral cytotoxic T lymphocyte (CTL) epitope peptides presented by classical MHC-I molecules require the assembly of a peptide-MHC-I-β2m (pMHC-I) trimolecular complex for T cell receptor (TCR) recognition, which is the critical activation link for triggering antiviral T cell immunity. Research on T cell immunology in the Ursidae family, especially structural immunology, is still lacking. In this study, the structure of the key trimolecular complex pMHC-I, which binds a peptide from canine distemper virus, was solved for the first time using giant panda as a representative species of Ursidae. The structural characteristics of the giant panda pMHC-I complex (pAime-128), including the unique pockets in the peptide-binding groove (PBG), were analyzed in detail. Comparing the pAime-128 to others in the bear family and extending the comparison to other mammals revealed distinct features. The interaction between MHC-I and β2m, the features of pAime-128 involved in TCR docking and cluster of differentiation 8 (CD8) binding, the anchor sites in the PBG, and the CTL epitopes of potential viruses that infect pandas were clarified. Unique features of pMHC-I viral antigen presentation in the panda were revealed by solving the three-dimensional (3D) structure of pAime-128. The distinct characteristics of pAime-128 indicate an unusual event that emerged during the evolution of the MHC system in the bear family. These results provide a new platform for research on panda CTL immunity and the design of vaccines for application in the bear family.

Identification of Novel Cytotoxic T Lymphocyte Epitopes of Drug- Resistance Related Protein InhA from Mycobacterium tuberculosis.

Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB), especially the drug-resistant MTB, poses serious challenges to human healthcare worldwide. Cytotoxic T lymphocytes (CTLs) play a vital role in immune defense against MTB. To identify novel CTL epitopes that could induce cellular immunity against MTB infections. The HLA-A*0201 restricted CTL epitopes of the drug-resistant protein InhA from MTB were predicted by online algorisms and synthesized by the Fmoc solid phase method. The candidate peptides were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*0201 healthy donors and the HLA-2.1/Kb mice. IFN-γ productions of CTLs were detected by enzyme linked immunospot assay (ELISPOT), flow cytometry and enzyme-linked immunosorbent assay (ELISA), and cytotoxicity was analyzed by lactate dehydrogenase (LDH) assay. A group of 4 epitopes were screened out with high affinities to HLA-A*0201. ELISPOT and flow cytometry analysis indicated these peptides significantly induced that IFN-γ release of CTLs from the HLA-A*0201+/PPD+ donors, as the mutant analogues had more potent stimulation effects. LDH assay showed that CTLs from PPD+ donors and the immunized mice exhibited significant cytotoxicity and low cross-reactivity. ELISA analysis revealed comparative levels of IFN-γ were released by CTLs isolated from the mice spleen. Our study has identified 4 novel CTL epitopes of InhA that could elicit potent CTL immunity, establishing a foundation for the development of multivalent peptide vaccines against the drug-resistant MTB.

Structures of the MHC-I molecule BF2*1501 disclose the preferred presentation of an H5N1 virus-derived epitope

Lethal infections by strains of the highly-pathogenic avian influenza virus (HPAIV) H5N1 pose serious threats to both the poultry industry and public health worldwide. A lack of confirmed HPAIV epitopes recognized by cytotoxic T lymphocytes (CTLs) has hindered the utilization of CD8+ T-cell-mediated immunity and has precluded the development of effectively diversified epitope-based vaccination approaches. In particular, an HPAIV H5N1 CTL-recognized epitope based on the peptide MHC-I-β2m (pMHC-I) complex has not yet been designed. Here, screening a collection of selected peptides of several HPAIV strains against a specific pathogen-free pMHC-I (pBF2*1501), we identified a highly-conserved HPAIV H5N1 CTL epitope, named HPAIV-PA123-130 We determined the structure of the BF2*1501-PA123-130 complex at 2.1 Å resolution to elucidate the molecular mechanisms of a preferential presentation of the highly-conserved PA123-130 epitope in the chicken B15 lineage. Conformational characteristics of the PA123-130 epitope with a protruding Tyr-7 residue indicated that this epitope has great potential to be recognized by specific TCRs. Moreover, significantly increased numbers of CD8+ T cells specific for the HPAIV-PA123-130 epitope in peptide-immunized chickens indicated that a repertoire of CD8+ T cells can specifically respond to this epitope. We anticipate that the identification and structural characterization of the PA123-130 epitope reported here could enable further studies of CTL immunity against HPAIV H5N1. Such studies may aid in the development of vaccine development strategies using well-conserved internal viral antigens in chickens.

AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.

Immune resistance may arise from both genetic instability and tumor heterogeneity. Microenvironmental stresses such as hypoxia and various resistance mechanisms promote carcinoma cell plasticity. AXL, a member of the TAM (Tyro3, Axl, and Mer) receptor tyrosine kinase family, is widely expressed in human cancers and increasingly recognized for its role in cell plasticity and drug resistance. To investigate mechanisms of immune resistance, we studied multiple human lung cancer clones derived from a model of hypoxia-induced tumor plasticity that exhibited mesenchymal or epithelial features. We demonstrate that AXL expression is increased in mesenchymal lung cancer clones. Expression of AXL in the cells correlated with increased cancer cell-intrinsic resistance to both natural killer (NK)- and cytotoxic T lymphocyte (CTL)-mediated killing. A small-molecule targeting AXL sensitized mesenchymal lung cancer cells to cytotoxic lymphocyte-mediated killing. Mechanistically, we showed that attenuation of AXL-dependent immune resistance involved a molecular network comprising NF-κB activation, increased ICAM1 expression, and upregulation of ULBP1 expression coupled with MAPK inhibition. Higher ICAM1 and ULBP1 tumor expression correlated with improved patient survival in two non-small cell lung cancer (NSCLC) cohorts. These results reveal an AXL-mediated immune-escape regulatory pathway, suggest AXL as a candidate biomarker for tumor resistance to NK and CTL immunity, and support AXL targeting to optimize immune response in NSCLC.

Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy.

With emerging success in fighting off cancer, chronic infections, and autoimmune diseases, immunotherapy has become a promising therapeutic approach compared to conventional therapies such as surgery, chemotherapy, radiation therapy, or immunosuppressive medication. Despite the advancement of monoclonal antibody therapy against immune checkpoints, the development of safe and efficient cancer vaccine formulations still remains a pressing medical need. Anti-tumor immunotherapy requires the induction of antigen-specific CD8+ cytotoxic T lymphocyte (CTL) responses which recognize and specifically destroy tumor cells. Due to the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity, targeting tumor antigens to DCs has become auspicious in modern vaccine research. Over the last two decades, micron- or nanometer-sized particulate delivery systems encapsulating tumor antigens and immunostimulatory molecules into biodegradable polymers have shown great promise for the induction of potent, specific and long-lasting anti-tumor responses in vivo. Enhanced vaccine efficiency of the polymeric micro/nanoparticles has been attributed to controlled and continuous release of encapsulated antigens, efficient targeting of antigen presenting cells (APCs) such as DCs and subsequent induction of CTL immunity. Poly (D, L-lactide-co-glycolide) (PLGA), as one of these polymers, has been extensively studied for the design and development of particulate antigen delivery systems in cancer therapy. This review provides an overview of the current state of research on the application of PLGA microspheres (PLGA MS) as anti-tumor cancer vaccines in activating and potentiating immune responses attempting to highlight their potential in the development of cancer therapeutics.

Risk Factors and Predictive Scoring System for Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation

Risk Factors and Predictive Scoring System for Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation

PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment

The Cancer-Immunity Cycle is a series of anticancer immune responses initiated and allowed to proceed and expand iteratively. Paclitaxel (PTX) is a classic chemotherapeutic agent, which could induce immunogenic cell death (ICD) to trigger the Cancer-Immunity Cycle. However, the Cycle is severely impaired by tumor cell immunosuppression of host T cell antitumor activity through the programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) (PD-1/PD-L1) immune checkpoint pathway. Here, we demonstrated that PTX mediated the Cancer-Immunity Cycle could be enhanced by PD-L1 knockdown (KD) and followed mTOR pathway inhibition in tumor cells. PD-L1 siRNA (siP) and the hydrophobic chemotherapy drug PTX were co-delivered with a rationally designed hybrid micelle (HM). We showed clear evidence that the HM-siP/PTX is capable of delivering siP and PTX simultaneously to the B16F10 cells both in vitro and in vivo. We demonstrated that HM-PTX/siP reduced the expression of PD-L1 and p-S6K (a marker of mTOR pathway activation) both in vitro and in melanoma-bearing mice and attenuated synergistically tumor growth by chemical toxicity, promoting cytotoxic T-cell immunity and suppressing the mTOR pathway.

DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors

Eukaryotic cells constitutively produce nanovesicles of 50-150nm of diameter, referred to as exosomes, upon release of the contents of multivesicular bodies (MVBs). We recently characterized a novel, exosome-based way to induce cytotoxic T lymphocyte (CTL) immunization against full-length antigens. It is based on DNA vectors expressing products of fusion between the exosome-anchoring protein Nef mutant (Nefmut) with the antigen of interest. The strong efficiency of Nefmut to accumulate in MVBs results in the production of exosomes incorporating huge amounts of the desired antigen. When translated in animals, the injection of Nefmut-based DNA vectors generates engineered exosomes whose internalization in antigen-presenting cells induces cross-priming and antigen-specific CTL immunity. Here, we describe the molecular strategies we followed to produce DNA vectors aimed at generating immunogenic exosomes potentially useful to elicit a CTL immune response against antigens expressed by the etiologic agents of major chronic viral infections, i.e., HIV-1, HBV, and the novel tumor-associated antigen HOXB7. Unique methods intended to counteract intrinsic RNA instability and nuclear localization of the antigens have been developed. The success we met with the production of these engineered exosomes opens the way towards pre-clinic experimentations devoted to the optimization of new vaccine candidates against major infectious and tumor pathologies.

Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model

Live attenuated influenza vaccines (LAIVs) are promising tools for the induction of broad protection from influenza due to their ability to stimulate cross-reactive T cells against influenza pathogens. One of the major targets for cytotoxic T-cell immunity is viral nucleoprotein (NP), which is relatively conserved among antigenically distant influenza viruses. Nevertheless, a diversity of epitope composition has been found in the NP protein of different lineages of influenza A viruses. The H2N2 master donor virus which is currently used as a backbone for the LAIV and donor of the six genomic segments encoding the internal proteins, A/Leningrad/134/17/57 (MDV Len/17), was isolated 60 years ago. As such, NP-specific T-cell immunity induced upon vaccination with classical LAIVs with a 6:2 genome composition containing this older NP might be suboptimal against currently circulating influenza viruses. In this study, a panel of H3N2 LAIV candidates with wild-type NP genes derived from circulating viruses were generated by reverse genetics (5:3 genome composition). These viruses displayed the cold adaptation and temperature sensitivity phenotypes of MDV Len/17 in vitro. LAIVs with both 6:2 and 5:3 genome compositions were attenuated and replicated to a similar extent in the upper respiratory tract of ferrets. LAIVs were immunogenic as high neutralizing and hemagglutination inhibition serum antibody titers were detected 21 days after infection. All vaccinated animals were protected against infection with heterologous H3N2 influenza A viruses. Thus, LAIV with a 5:3 genome composition is safe, immunogenic and can induce cross-protective immunity.

Stability of CTL immunity pathogen dynamics model with capsids and distributed delay

In this paper, a pathogen dynamics model with capsids and saturated incidence has been proposed and analyzed. Cytotoxic T Lymphocyte (CTL) immune response and two distributed time delays have been incorporated into the model. The nonnegativity and boundedness of the solutions of the proposed model have been shown. Two threshold parameters which fully determine the existence and stability of the three steady states of the model have been computed. Using the method of Lyapunov function, the global stability of the steady states of the model has been established. The theoretical results have been confirmed by numerical simulations.